×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AKBA – akebia therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AKBA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
07:48 am
akba
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years [Yahoo! Finance]
Medium
Report
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years [Yahoo! Finance]
12/18
08:14 am
akba
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
08:00 am
akba
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/13
02:06 am
akba
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
12/4
11:21 pm
akba
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
12/3
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
07:18 am
akba
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis [Yahoo! Finance]
Medium
Report
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis [Yahoo! Finance]
12/3
07:00 am
akba
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
Medium
Report
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
Date
Time
Symbol
Company Name
Action
%Chg
5/9/2024
07:00 am
akba
akebia therapeutics, inc.
IN-LINE
Report
3.1%
akebia therapeutics, inc.
3/14/2024
04:15 pm
akba
akebia therapeutics, inc.
BEAT
Report
24.1%
akebia therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/8
02:18 pm
akba
Form SC 13G Akebia Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Akebia Therapeutics, Filed by: BlackRock, Inc.
11/7
07:17 am
akba
Form 10-Q Akebia Therapeutics, For: Sep 30
Low
Report
Form 10-Q Akebia Therapeutics, For: Sep 30
11/7
07:06 am
akba
Form 8-K Akebia Therapeutics, For: Nov 07
Low
Report
Form 8-K Akebia Therapeutics, For: Nov 07
10/22
06:07 pm
akba
Form SC 13G Akebia Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Akebia Therapeutics, Filed by: BlackRock, Inc.
10/22
08:06 am
akba
Form 8-K Akebia Therapeutics, For: Oct 22
High
Report
Form 8-K Akebia Therapeutics, For: Oct 22
10/16
07:36 am
akba
Form 8-K Akebia Therapeutics, For: Oct 15
Low
Report
Form 8-K Akebia Therapeutics, For: Oct 15
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock.
34.5%
11/22 Form 4 Akebia Therapeutics, For: Nov 20 Filed by: Smith Cynthia 21.7%
3/23 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 16.2%
8/8 Q2/2019 6/30/2019 EPS -0.490 ZacksConsensus -0.350 ActVsEst (0.140) - Miss 13.9%
3/13 Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates [Yahoo! Finance News] 13.2%
3/10 Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.2%
3/23 Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference 6.7%
8/8 Form 10-Q Akebia Therapeutics, For: Jun 30 5.8%
4/23 Form DEF 14A Akebia Therapeutics, For: Jun 05 5.3%
9/9 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock. 5.2%
11/22 Form 4 Akebia Therapeutics, For: Nov 20 Filed by: Smith Cynthia 21.7%
3/23 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 16.2%
8/8 Q2/2019 6/30/2019 EPS -0.490 ZacksConsensus -0.350 ActVsEst (0.140) - Miss 13.9%
3/13 Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates [Yahoo! Finance News] 13.2%
3/10 Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.2%
3/23 Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference 6.7%
8/8 Form 10-Q Akebia Therapeutics, For: Jun 30 5.8%
4/23 Form DEF 14A Akebia Therapeutics, For: Jun 05 5.3%
9/9 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock. 5.2%
TOP News Decliners
3/15
A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:
-14.5%
11/12 Q3/2019 9/30/2019 EPS -0.460 ZacksConsensus -0.370 ActVsEst (0.090) - Miss -14.4%
12/2 Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years [Yahoo! Finance News] -14.1%
3/18 Form SEC STAFF LETTER Akebia Therapeutics, -13.1%
11/9 Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease -9.9%
8/2 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.0%
6/4 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.6%
3/10 Q4/2019 12/31/2019 EPS -0.790 ZacksConsensus -0.440 ActVsEst (0.350) - Miss -7.6%
8/2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.8%
3/11 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock, down previously from $16.00. -6.6%
11/12 Q3/2019 9/30/2019 EPS -0.460 ZacksConsensus -0.370 ActVsEst (0.090) - Miss -14.4%
12/2 Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years [Yahoo! Finance News] -14.1%
3/18 Form SEC STAFF LETTER Akebia Therapeutics, -13.1%
11/9 Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease -9.9%
8/2 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.0%
6/4 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.6%
3/10 Q4/2019 12/31/2019 EPS -0.790 ZacksConsensus -0.440 ActVsEst (0.350) - Miss -7.6%
8/2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.8%
3/11 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock, down previously from $16.00. -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: